Rochester, NY 7/10/2009 9:42:18 PM
Stock Exchange News - RPRX - RPRX Shares Amendment to NIH License Agreement relating on the Proellex - Sourced WhisperFromWallStreet.com
Repros Therapeutics Inc.
Stock Exchange News - RPRX - RPRX Shares Amendment to NIH License Agreement relating on the Proellex - Sourced WhisperFromWallStreet.com
COMPANY - Repros Therapeutics Inc.,RPRX
NEWS - Repros Therapeutics, Inc.today announced that it entered into the Sixth Amendment to its Agreement with the National Institutes of Health relating to the Company’s lead product Proellex. The Amendment clarified that certain cancers related to the human reproductive system are within the scope of the licensed field, amended the development and commercialization benchmarks that the Company is required to meet under the Agreement and added or modified certain milestone payments due to NIH on the achievement of certain benchmarks.Most significantly, the Amendment revised the dates by which certain development and commercialization benchmarks must be met.
Real-Time: 7.60 Up 0.04 (0.53%) 9:34AM ET
Last Trade: 4.35
Day's Range: 4.35 - 4.41
52wk Range: 4.20 - 13.94
Volume: 900
ABOUT - Repros Therapeutics Inc., a development stage biopharmaceutical company, focuses on the development of oral small molecule drugs for the treatment of male and female reproductive disorders. Its lead drug includes Proellex, a selective blocker of the progesterone receptor, which is in Phase III clinical trials for use as a pre-surgical treatment for women with anemia due to excessive menstrual bleeding associated with uterine fibroids, or anemia associated with uterine fibroids; in Phase III clinical trials for the chronic treatment of symptoms associated with uterine fibroids; and in Phase II clinical trials for the chronic treatment of symptoms associated with endometriosis.
---
WhisperFromWallStreet is a news letter focusing on sending specific alerts to our subscribers. These alerts represent which stocks we believe are going to run. Additionally we spend time teaching how to become a better trader. If you like more information or to Sign Up for free alerts, visit us at WhisperfromWallStreet.com
Disclaimer: Full disclaimer at http://whisperfromwallstreet.com/disclaimer.php
IMPORTANT INFORMATION: Nothing in this press release should be interpreted as a solicitation to buy any stock or security represented herein. WhisperfromWallStreet, nor any of its affiliates are registered investment advisors or broker dealers. Information presented here is based on our opinion only.
